Patents
Patents for C07C 233 - Carboxylic acid amides (28,881)
03/2005
03/31/2005WO2004113270A3 Propionic acid derivatives useful in the treatment of lipid disorders
03/31/2005CA2536439A1 Process for the synthesis of 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-7-ethoxy-quinoline-3-carbonitrile
03/30/2005EP1517884A1 A process for the preparation of 3-cyano-1-naphthoic acid and some analogues thereof
03/30/2005EP1517882A1 Amide linker peroxisome proliferator activated receptor modulators
03/30/2005EP1517881A1 4-(3,3-dihalo-allyloxy)phenoxy alkyl derivatives
03/30/2005EP1517880A2 Production of cis-pellitorin and use as a flavouring
03/30/2005EP1517879A1 Aminoalkylphenols, methods of using and making the same
03/30/2005EP1517680A1 Benzoic acid derivatives as modulators of ppar alpha and gamma
03/30/2005EP1435912A4 Novel stable crystal form of n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanine and process of preparation
03/30/2005EP1224163B1 Use of carbonylamino derivatives against cns disorders
03/30/2005EP1192127B1 Substituted benzamide inhibitors of rhinovirus 3c protease
03/30/2005CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
03/30/2005CN1600772A Aryl phenyl substituted cyclic ketoenols
03/30/2005CN1194960C Method for preparing 4,5-diamino shikimic acid derivative
03/29/2005US6872852 Polyamine analogues as cytotoxic agents
03/29/2005US6872851 Melatonergic receptors; antiinflammatory agents; anticancer agents
03/29/2005US6872842 Butenyl substituted taxanes
03/29/2005US6872735 LFA-1 antagonist compounds
03/29/2005CA2176042C Alpha-aryl or heteroaryl-substituted amide ester acat inhibitors
03/24/2005WO2005026372A1 Polyethyleneglycol-modified lipid compounds and uses thereof
03/24/2005WO2005026134A1 Organic compounds
03/24/2005WO2005025555A2 Combinations of an aryl aniline beta-2 adrenergic receptor agonist and a corticosteroid
03/24/2005WO2005025314A1 Capsaicin derivates and the production and use thereof
03/24/2005WO2005012220A3 Cycloalkylidene compounds as modulators of estrogen receptor
03/24/2005WO2005005389A3 Malonamide derivatives
03/24/2005WO2004071426A3 Compounds for the treatment of viral infection
03/24/2005WO2004060882A8 Cb 1/cb 2 receptor ligands and their use in the treatment of pain
03/24/2005WO2004046162A8 Non-steroidal fxr agonists
03/24/2005US20050065367 Method for producing optically active beta-phenylalanine
03/24/2005US20050065366 Method for producing optically active beta-phenylalanine compounds
03/24/2005US20050065339 Amino-alkyl derivatives
03/24/2005US20050065191 Central nervous system disorders; therapy for diseases of glutamate receptor signal transmission
03/24/2005US20050065188 Aryl or heteroaryl amide compounds
03/24/2005US20050065181 Using 3-(4-acetamido-3-chloroanilino)- 2-cyanopropionenic acid ester ester as chemical intermediate; acylation, alkylation, reduction, cyclization, chlorination, hydrolysis
03/24/2005CA2551022A1 Polyethyleneglycol-modified lipid compounds and uses thereof
03/24/2005CA2539016A1 Organic compounds
03/24/2005CA2530510A1 Improved delivery by labile hydrophobic modification of drugs
03/23/2005EP1516041A1 Use of transition metal complexes with nitrogen-containing polydentate ligands as a bleaching catalyst and bleaching agent composition
03/23/2005EP1515944A1 Aspartyl protease inhibitors
03/23/2005EP1515942A1 Carboxamides derivatives
03/23/2005EP1515940A2 Aminoalkoxy-functional chalcones
03/23/2005EP1515926A2 Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia
03/23/2005EP1187859A4 Polymer gels, methods for their preparation and their use in electrophoretic applications
03/23/2005EP1091924A4 Novel retinoids and use thereof
03/23/2005CN1599743A Ligands for use in catalytic processes
03/23/2005CN1193982C Process for prepraring p-acetpamidophenol
03/23/2005CN1193748C Gardos channel antagonists
03/22/2005US6870069 Carbocyclic oxy amides such as N-(2-fluoromethyl-5-methoxy-benzyl)-N-(5-fluoro-2-phenoxyphenyl)acetamide, used as preferential ligands for peripheral benzodiazepine receptors having high receptivity; anxiolytic agents
03/22/2005US6870065 Such as N-hydroxysuccinimidyl-5-(N,N-bis-(2-(4-(N-((3-hydroxy-4-(methoxy-carbonyl) phenyl)methyl)carbamoyl) butanoylamino)ethyl)carbamoyl)butanoate for biochemical conjugation
03/22/2005US6869957 Non-peptide tachykinin receptor antagonists
03/22/2005US6869953 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents
03/22/2005US6869605 Anticarcinogenic agents
03/22/2005CA2225250C Bicyclic amino derivatives and pgd2 antagonist containing the same
03/17/2005WO2005023808A2 Process for the preparation of renzapride and intermediates thereof
03/17/2005WO2005023765A1 Method for catalyzing amidation reactions by the presence of co2
03/17/2005WO2005023242A1 Entry inhibitors of the hiv virus
03/17/2005WO2004111008A3 Use of a compound of formula i for making a pharmaceutical composition
03/17/2005WO2004083867A3 Modulators of g protein-coupled formyl peptide receptor-like 2 and their therapeutic use against cell death-related disorders
03/17/2005US20050059841 Processes for the preparation of a carobxylic anhydride and use of the carboxylic anhydride as an acylation agent
03/17/2005US20050059824 Using carbon dioxide; salt formation, hydrolysis
03/17/2005US20050059735 Cyclic amino acid derivatives useful as pharmaceutical agents
03/17/2005US20050059729 Substituted cyclic compounds
03/17/2005US20050059713 Antiviral agents for the treatment, preventions, or amelioration of viral infections; for example, 3-Biphenyl-4-yl-(2S)-[(3'-chloro-4'-fluoro-4-hydroxy-biphenyl-3-carbonyl)-amino]-propionic acid methyl ester
03/17/2005US20050059705 May be antagonists of the intrinsic clotting pathway by binding to and inhibiting the function of factor XI or of both factors XI and IX; for example, 2(S)-{[7-(4-tert-Butyl-phenoxy)-1-cyclopentylmethyl-isoquinoline-3-carbonyl]-amino}-3-(5-phenyl-thiophen-2-yl)-propionic acid; anticoagulants
03/17/2005US20050059648 Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof
03/17/2005US20050058734 Relieving pain by injecting or infiltrating implantable dose of a capsaicinoid to denervate and vasoconstrictor; cancer, trauma, headache, diabetes, arthritic and/or neuropathic pain; local anesthetics
03/17/2005US20050058604 Phthalamide-lanthanide complexes for use as luminescent markers
03/17/2005CA2537536A1 Process for the preparation of renzapride and intermediates thereof
03/16/2005EP1514912A2 Phase change inks containing branched triamides
03/16/2005EP1514867A2 Substituted phenyl derivatives, their preparation and use
03/16/2005EP1513892A1 Conversion products of mixtures of long-chained fatty acids and aliphatic diamines, and the use thereof
03/16/2005EP1513818A2 Heterocyclic inhibitors of kinases
03/16/2005EP1513803A1 Ligands that are inhibitors of the rar receptors
03/16/2005EP1513795A2 Propionic acid derivatives and their use as hppars activators
03/16/2005EP1341799B1 P-chirale bisphospholane ligands, their transition metal complexes
03/16/2005EP1215200B1 Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same
03/16/2005EP0874625B1 Indane derivatives for antipsychotic compositions
03/16/2005CN1596250A Paclitaxel solvates
03/16/2005CN1594283A Process for preparing N-acetyl-L-tyrosine
03/16/2005CN1593230A Alkyldienamides exhibiting taste and sensory effect in flavor compositions
03/16/2005CN1193019C Method and reagents for N-alkylating ureides
03/16/2005CN1193005C Preparation method for amide
03/16/2005CN1193000C Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cometic compositions containing same
03/16/2005CN1192711C Compound of fungicide and insecticide
03/15/2005US6867310 Synthesize efficiently and under mild conditions alpha -aryl and alpha -vinyl products from a wide range of starting materials, including ketones, esters, hydrazones, and imines, enantiomorphs
03/15/2005US6867298 Group IB compounds used as condensation, amination, amidation or arylation catalysts; catalysis; efficiency
03/15/2005US6867171 Liquids; easy to handle; paper chemicals, lubricants, dis-persants, detergents
03/15/2005US6866863 Ingestibles possessing intrinsic color change
03/10/2005WO2005021508A1 Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
03/10/2005WO2005021486A1 Ester derivative and medicinal use thereof
03/10/2005WO2005021472A2 Fluoridation of electron rich aromatic systems
03/10/2005WO2005021051A1 Aminoalkyl substituted esters and amides of fumaric acid for neutralising malodor
03/10/2005WO2005020882A2 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005WO2004018408A8 Synthesis and purification of nateglinide
03/10/2005WO2003007875A9 Compounds with analgesic, antipyretic and/or anti-inflammatory activity
03/10/2005US20050054883 1-hydroxy-1-(5-norbornene-2-yl)-2,2,4,4,4-pentafluorobutane-3-one; 1-(5-norbornene-2-yl)-2,2,4,4,4-pentafluorobutane-1,3,3-triol; excellent in transparency to irradiation, dry etching resistance, has low hydrophobicity, excellent in development characteristics, useful for photoresist resin
03/10/2005US20050054882 Diaryl ether condensation reactions
03/10/2005US20050054873 Process for the preparation of aniline-derived thyroid receptor ligands
03/10/2005US20050054729 Combined with a statin, ACE-inhibitor, PDE V-inhibitor, Ca-antagonist, beta-blocker, arginine, or tetrahydrobiopterin; treating of conditions including cardiovascular disorders, erectile dysfunction, therapy and prophylaxis of diabetes including its complicatons, and respiratory diseases
03/10/2005US20050054727 For treating or delaying progression or onset of obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, non-toxic goiter, reduced bone mass, density or growth, eating disorders, cardiac arrhythmia